Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Eugenia Abaleke(University of Siena), Emmanuel O Adewunmi, Kirsty Adcock, Sadia Abbasi, Ahmed Abou-Haggar, Abraheem Abraheem, Janet Acheson(University of Dundee), Althaf Abdul Rasheed, Jacqueline Adabie-Ankrah, Yazeed Abed El Khaleq, Judith Abrams, Richard Adams(Velindre Cancer Centre), Sherna Adenwalla, Alfie Abbott, Matthew Adam, Basir Abdul, Mustafa Abbas, Niyaz Abdulshukkoor, Malgorzata Adamus, Kula Abdusamad, Akata Abung, Catherine Acton, Carol Adams, Aldrin Adeni, Yaa Aceampong, Miriam Abraham, Hani Abo-Leyah(University of Dundee), Kate Adams, Huzaifa Adamali, Syed M Abubacker, Ashraf Omar Abdelaziz(Ain Shams University), Andrés Acosta(Mayo Clinic), Adebanke Aboaba, Tim Adams, Oluwasegun A Adesemoye, Ken Adegoke(National Health and Medical Research Council), Ahmad Abu-Arafeh, Mohamed A. O. Abdelfattah, Vicki Adell, Sherif Abdelbadiee, Abdulfatahi Abdulmumeen, Hyacinth-John Abu(University of Dundee), Rezan A. Kadir(The Royal Free Hospital), Aderonke Adebiyi, Fiona Adam, Devikumar Acharya, Abeer UA Abeer Ul Amna, Mai Abedalla, Tizzy Abraham, Mahmoud Abouibrahim
Cited by 564
Related Papers
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
|The Lancet|2021|523
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
|The Lancet|2022|384
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
|The Lancet|2022|329
Clinical development of new drug–radiotherapy combinations
|Nature Reviews Clinical Oncology|2016|317